Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in: Archives of Gynecology and Obstetrics 6/2013

01.06.2013 | Gynecologic Oncology

Ovarian epithelial tumors and reproductive factors: a systematic review

verfasst von: Susanne Schüler, Marvin Ponnath, Jörg Engel, Olaf Ortmann

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this systematic review is to summarize the current knowledge about the etiology and pathogenesis of borderline tumors ovarian cancer with special emphasis on the role of endocrine treatments and reproductive factors to establish a foundation for future studies.

Methods

We performed a systematic review on the relation between ovarian epithelial tumors (OET) and reproductive factors using the keywords: ovarian cancer, ovarian tumor, ovarian borderline tumor, age at menarche, age at menopause, parity, infertility, PCO syndrome, oral contraception, menopausal hormone therapy, fertility treatment. Totally, 3,290 abstracts were scanned for their relevance in this publication and 127 were finally included.

Results

The incidence of ovarian epithelial cancer and ovarian borderline tumors is influenced by certain reproductive factors. The strongest protective effects are conferred by parity and use of oral contraceptive pills. Recent molecular biologic and histopathologic studies prove that OET represent a diverse group of tumors, each histologic type with a different genetic background. This is at least partly reflected in epidemiologic and clinical studies showing different risk modulating effects of reproductive factors and endocrine therapies on OET.

Conclusions

The etiology and pathogenesis of ovarian cancer are still not fully understood. None of the so far proposed hypothesis on the development of OET can fully account for the epidemiologic and clinical findings in the context of reproductive factors and OET development. Further research approaches are warranted and need to put more weight on the clinical and genetical diversity of OET to yield a more detailed insight into their pathogenesis.
Literatur
1.
2.
Gershenson DM (2002) Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 16(4):513–527. pii: S1521693402903081PubMedCrossRef
3.
Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65(22):10602–10612. doi:10.​1158/​0008-5472.​CAN-05-2240 PubMedCrossRef
4.
5.
Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, Devesa S (2004) Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100(5):1045–1052. doi:10.​1002/​cncr.​20080 PubMedCrossRef
6.
7.
Burks RT, Sherman ME, Kurman RJ (1996) Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 20(11):1319–1330PubMedCrossRef
8.
Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496–504. pii: 00000478-200404000-00009PubMedCrossRef
9.
Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, Malpica A, Stoler MH, Kurman RJ (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35(8):934–948. pii: S0046817704001546PubMedCrossRef
10.
11.
Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160(4):1223–1228. pii: S0002-9440(10)62549-7PubMedCrossRef
12.
Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484–486PubMedCrossRef
13.
14.
Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ, deFazio A, Chenevix-Trench G, Bowtell DD (2008) Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 6(11):1678–1690. doi:10.​1158/​1541-7786.​MCR-08-0193 PubMedCrossRef
15.
16.
Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221(1):49–56. doi:10.​1002/​path.​2696 PubMedCrossRef
17.
18.
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069–1075. doi:10.​1038/​nature07423 PubMedCrossRef
19.
20.
21.
Hart WR (2005) Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 24(1):4–25. pii: 00004347-200501000-00003PubMed
22.
Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM (1991) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139(4):777–785PubMed
23.
Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90(2):378–381. pii: S0090825803002646PubMedCrossRef
24.
25.
Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53(7):1489–1492PubMed
26.
Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198(4):351–356. doi:10.​1016/​j.​ajog.​2008.​01.​005 PubMedCrossRef
27.
28.
Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih Ie M (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174(5):1597–1601. doi:10.​2353/​ajpath.​2009.​081000 PubMedCrossRef
29.
Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O (2011) PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 225(2):189–194. doi:10.​1002/​path.​2940 PubMedCrossRef
30.
Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O (2011) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. doi:10.​1038/​modpathol.​2011.​189
31.
Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O (2011) Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol 24(8):1146–1155. doi:10.​1038/​modpathol.​2011.​70 PubMedCrossRef
32.
33.
Wu R, Zhai Y, Fearon ER, Cho KR (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61(22):8247–8255PubMed
34.
Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J (2001) Beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 10(2):116–122PubMedCrossRef
35.
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih Ie M, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(16):1532–1543. doi:10.​1056/​NEJMoa1008433 PubMedCrossRef
36.
Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58(10):2095–2097PubMed
37.
38.
Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60(24):7052–7056PubMed
39.
Prowse AH, Manek S, Varma R, Liu J, Godwin AK, Maher ER, Tomlinson IP, Kennedy SH (2006) Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 119(3):556–562. doi:10.​1002/​ijc.​21845 PubMedCrossRef
40.
Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63–70. doi:10.​1038/​nm1173 PubMedCrossRef
41.
Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3 K/Pten signaling pathways. Cancer Cell 11(4):321–333. doi:10.​1016/​j.​ccr.​2007.​02.​016 PubMedCrossRef
42.
Kang SK, Choi KC, Cheng KW, Nathwani PS, Auersperg N, Leung PC (2000) Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 141(1):72–80PubMedCrossRef
43.
Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R (1989) Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25(2):215–221PubMedCrossRef
44.
Emons G, Ortmann O, Pahwa GS, Hackenberg R, Oberheuser F, Schulz KD (1992) Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Acta Obstet Gynecol Scand Suppl 155:31–38PubMed
45.
Irmer G, Burger C, Muller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz KD, Emons G (1995) Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55(4):817–822PubMed
46.
47.
Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD, Schally AV (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53(22):5439–5446PubMed
48.
Emons G, Pahwa GS, Ortmann O, Knuppen R, Oberheuser F, Schulz KD (1990) LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview. J Steroid Biochem Mol Biol 37(6):1003–1006. pii: 0960-0760(90)90457-VPubMedCrossRef
49.
50.
Ling Poon S, Lau MT, Hammond GL, Leung PC (2011) Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells. Endocrinology 152(3):764–772. doi:10.​1210/​en.​2010-0942 PubMedCrossRef
51.
Zheng W, Magid MS, Kramer EE, Chen YT (1996) Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 148(1):47–53PubMed
52.
Bose CK (2008) Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer. Oncol Res 17(5):231–238PubMedCrossRef
53.
Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK (2001) Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 172(1–2):213–222. pii: S0303-7207(00)00340-3PubMedCrossRef
54.
55.
56.
Mandai M, Konishi I, Kuroda H, Fukumoto M, Komatsu T, Yamamoto S, Nanbu K, Rao CV, Mori T (1997) Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur J Cancer 33(9):1501–1507. pii: S0959804997001664PubMedCrossRef
57.
Tourgeman DE, Lu JJ, Boostanfar R, Amezcua C, Felix JC, Paulson RJ (2002) Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil Steril 78(5):1096–1099. pii: S0015028202033678PubMedCrossRef
58.
Choi JH, Choi KC, Auersperg N, Leung PC (2004) Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 89(11):5508–5516. doi:10.​1210/​jc.​2004-0044 PubMedCrossRef
59.
Tashiro H, Katabuchi H, Begum M, Li X, Nitta M, Ohtake H, Okamura H (2003) Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and -independent growth in human ovarian surface epithelial cell lines. Cancer Sci 94(11):953–959PubMedCrossRef
60.
Ji Q, Liu PI, Chen PK, Aoyama C (2004) Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 112(5):803–814. doi:10.​1002/​ijc.​20478 PubMedCrossRef
61.
Lau MT, Wong AS, Leung PC (2010) Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 151(7):2985–2993. doi:10.​1210/​en.​2009-1318 PubMedCrossRef
62.
Schiffenbauer YS, Meir G, Maoz M, Even-Ram SC, Bar-Shavit R, Neeman M (2002) Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin. Gynecol Oncol 84(2):296–302. doi:10.​1006/​gyno.​2001.​6512 PubMedCrossRef
63.
Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Munstedt K, Rao CV, Lang U, Preissner KT (2002) Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 87(11):5290–5296PubMedCrossRef
64.
Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W (2002) VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 97(2):163–167. doi:10.​1002/​ijc.​1593 PubMedCrossRef
65.
Basille C, Olivennes F, Le Calvez J, Beron-Gaillard N, Meduri G, Lhomme C, Duvillard P, Benard J, Morice P (2006) Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours. Hum Reprod 21(12):3241–3245. doi:10.​1093/​humrep/​del301 PubMedCrossRef
66.
Heinonen PK, Koivula T, Rajaniemi H, Pystynen P (1986) Peripheral and ovarian venous concentrations of steroid and gonadotropin hormones in postmenopausal women with epithelial ovarian tumors. Gynecol Oncol 25(1):1–10PubMedCrossRef
67.
68.
Brandenberger AW, Tee MK, Jaffe RB (1998) Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 83(3):1025–1028PubMedCrossRef
69.
Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H (1992) Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 75(6):1497–1502PubMedCrossRef
70.
71.
Keith Bechtel M, Bonavida B (2001) Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol 82(1):127–138. doi:10.​1006/​gyno.​2001.​6221 PubMedCrossRef
72.
73.
Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61(18):6768–6776PubMed
74.
Bardin A, Moll F, Margueron R, Delfour C, Chu ML, Maudelonde T, Cavailles V, Pujol P (2005) Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 146(2):760–768. doi:10.​1210/​en.​2004-1239 PubMedCrossRef
75.
Yousef GM, Diamandis EP (2002) Kallikreins, steroid hormones and ovarian cancer: is there a link? Minerva Endocrinol 27(3):157–166PubMed
76.
Simpson BJ, Langdon SP, Rabiasz GJ, Macleod KG, Hirst GL, Bartlett JM, Crew AJ, Hawkins RA, Macineira-Perez PP, Smyth JF, Miller WR (1998) Estrogen regulation of transforming growth factor-alpha in ovarian cancer. J Steroid Biochem Mol Biol 64(3–4):137–145. pii: S0960-0760(97)00159-3PubMedCrossRef
77.
Wimalasena J, Meehan D, Dostal R, Foster JS, Cameron M, Smith M (1993) Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol Res 5(8):325–337PubMed
78.
Krywicki RF, Figueroa JA, Jackson JG, Kozelsky TW, Shimasaki S, Von Hoff DD, Yee D (1993) Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. Eur J Cancer 29A(14):2015–2019PubMedCrossRef
79.
Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O (2007) Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193(3):421–433. doi:10.​1677/​JOE-07-0087 PubMedCrossRef
80.
81.
Kang SK, Choi KC, Tai CJ, Auersperg N, Leung PC (2001) Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. Endocrinology 142(2):580–588PubMedCrossRef
82.
Treeck O, Haldar C, Ortmann O (2006) Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep 15(1):231–235PubMed
83.
84.
85.
Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G, Darai E (2006) Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep 15(4):743–748PubMed
86.
Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM (2007) Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 102(2):442–452. doi:10.​1002/​jcb.​21304 PubMedCrossRef
87.
Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y (2008) Estrogen and progestin regulate metastasis through the PI3 K/AKT pathway in human ovarian cancer. Int J Oncol 33(5):959–967PubMed
88.
89.
Takahashi A, Kato K, Kuboyama A, Inoue T, Tanaka Y, Kuhara A, Kinoshita K, Takeda S, Wake N (2009) Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells. Gynecol Oncol 113(2):270–276. doi:10.​1016/​j.​ygyno.​2008.​12.​032 PubMedCrossRef
90.
Gabra H, Langdon SP, Watson JE, Hawkins RA, Cohen BB, Taylor L, Mackay J, Steel CM, Leonard RC, Smyth JF (1995) Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer. Clin Cancer Res 1(9):945–953PubMed
91.
Davis M, Hitchcock A, Foulkes WD, Campbell IG (1996) Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 56(4):741–744PubMed
92.
93.
94.
Peluso JJ, Gawkowska A, Liu X, Shioda T, Pru JK (2009) Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 150(11):4846–4854. doi:10.​1210/​en.​2009-0730 PubMedCrossRef
95.
96.
97.
Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, Castagna G (1998) Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 17(2):231–237PubMed
98.
99.
Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94(7):3320–3323PubMedCrossRef
100.
101.
Evangelou A, Jindal SK, Brown TJ, Letarte M (2000) Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 60(4):929–935PubMed
102.
103.
104.
105.
Schildkraut JM, Bastos E, Berchuck A (1997) Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 89(13):932–938PubMedCrossRef
106.
107.
108.
109.
Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih Ie M (2012) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma–evidence supporting the clonal relationship of the two lesions. J Pathol 226(3):421–426. doi:10.​1002/​path.​3023 PubMedCrossRef
110.
Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11(17):6116–6126. doi:10.​1158/​1078-0432.​CCR-04-2509 PubMedCrossRef
111.
Murdoch WJ, Martinchick JF (2004) Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood) 229(6):546–552
112.
Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71(4):717–721PubMed
113.
114.
Blaakaer J, Baeksted M, Micic S, Albrectsen P, Rygaard J, Bock J (1995) Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Biol Reprod 53(4):775–779PubMedCrossRef
115.
Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW (1976) Hormonal profiles after the menopause. Br Med J 2(6039):784–787PubMedCrossRef
116.
Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90(23):1774–1786PubMedCrossRef
117.
Silva EG, Tornos C, Fritsche HA Jr, el-Naggar A, Gray K, Ordonez NG, Luna M, Gershenson D (1997) The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 10(9):879–883PubMed
118.
Nishizuka Y, Sakakura T, Tsujimura T, Matsumoto K (1973) Steroid biosynthesis in vitro by dysgenetic ovaries induced by neonatal thymectomy in mice. Endocrinology 93(4):786–792PubMedCrossRef
119.
Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW (1995) Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274(24):1926–1930PubMedCrossRef
120.
Wynder EL, Dodo H, Barber HR (1969) Epidemiology of cancer of the ovary. Cancer 23(2):352–370PubMedCrossRef
121.
Sonnichsen AC, Lindlacher U, Richter WO, Schwandt P (1990) Obesity, body fat distribution and the incidence of breast, cervical, endometrial and ovarian carcinomas. Dtsch Med Wochenschr 115(50):1906–1910. doi:10.​1055/​s-2008-1065242 PubMedCrossRef
122.
Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies (2012). PLoS Med 9(4):e1001200. doi:10.​1371/​journal.​pmed.​1001200
123.
Olsen CM, Green AC, Nagle CM, Jordan SJ, Whiteman DC, Bain CJ, Webb PM (2008) Epithelial ovarian cancer: testing the ‘androgens hypothesis’. Endocr Relat Cancer 15(4):1061–1068. doi:10.​1677/​ERC-08-0075 PubMedCrossRef
124.
Kotsopoulos J, Baer HJ, Tworoger SS (2010) Anthropometric measures and risk of epithelial ovarian cancer: results from the nurses’ health study. Obesity (Silver Spring) 18(8):1625–1631. doi:10.​1038/​oby.​2009.​461 CrossRef
125.
Lahmann PH, Cust AE, Friedenreich CM, Schulz M, Lukanova A, Kaaks R, Lundin E, Tjonneland A, Halkjaer J, Severinsen MT, Overvad K, Fournier A, Chabbert-Buffet N, Clavel-Chapelon F, Dossus L, Pischon T, Boeing H, Trichopoulou A, Lagiou P, Naska A, Palli D, Grioni S, Mattiello A, Tumino R, Sacerdote C, Redondo ML, Jakszyn P, Sanchez MJ, Tormo MJ, Ardanaz E, Arriola L, Manjer J, Jirstrom K, Bueno-de-Mesquita HB, May AM, Peeters PH, Onland-Moret NC, Bingham S, Khaw KT, Allen NE, Spencer E, Rinaldi S, Slimani N, Chajes V, Michaud D, Norat T, Riboli E (2010) Anthropometric measures and epithelial ovarian cancer risk in the European prospective investigation into cancer and nutrition. Int J Cancer 126(10):2404–2415. doi:10.​1002/​ijc.​24952 PubMed
126.
Rinaldi S, Dossus L, Lukanova A, Peeters PH, Allen NE, Key T, Bingham S, Khaw KT, Trichopoulos D, Trichopoulou A, Oikonomou E, Pera G, Larranaga N, Martinez-Garcia C, Ardanaz E, Quiros JR, Tormo MJ, Tjonneland A, Olsen A, Overvad K, Chang-Claude J, Linseisen J, Schulz M, Boeing H, van Gils CH, Bueno-de-Mesquita BH, Pala V, Palli D, Panico S, Tumino R, Vineis P, Clavel-Chapelon F, Mesrine S, Boutron-Ruault MC, Lundin E, Agren A, Berglund G, Manjer J, Kumle M, Lund E, Slimani N, Saracci R, Riboli E, Kaaks R (2007) Endogenous androgens and risk of epithelial ovarian cancer: results from the European prospective investigation into cancer and nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 16(1):23–29. doi:10.​1158/​1055-9965.​EPI-06-0755 PubMedCrossRef
127.
Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, Nomura AM, Terada KY, Carney ME, Sobin LH (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158(7):629–638PubMedCrossRef
128.
Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, Lund E, Fournier A, Overvad K, Hansen L, Tjonneland A, Fedirko V, Rinaldi S, Romieu I, Clavel-Chapelon F, Engel P, Kaaks R, Schutze M, Steffen A, Bamia C, Trichopoulou A, Zylis D, Masala G, Pala V, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodriguez L, Travier N, Sanchez MJ, Huerta JM, Ardanaz E, Larranaga N, Jirstrom K, Manjer J, Idahl A, Ohlson N, Khaw KT, Wareham N, Mouw T, Norat T, Riboli E (2011) Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 105(9):1436–1442. doi:10.​1038/​bjc.​2011.​371 PubMedCrossRef
129.
Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL (2012) Age at menarche and risk of ovarian cancer: A meta-analysis of epidemiological studies. Int J Cancer. doi:10.​1002/​ijc.​27952
130.
Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, Kjaer SK (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16(6):1160–1166. doi:10.​1158/​1055-9965.​EPI-07-0089 PubMedCrossRef
131.
Braem MG, Onland-Moret NC, van den Brandt PA, Goldbohm RA, Peeters PH, Kruitwagen RF, Schouten LJ (2010) Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 172(10):1181–1189. doi:10.​1093/​aje/​kwq264 PubMedCrossRef
132.
Pelucchi C, Galeone C, Talamini R, Bosetti C, Montella M, Negri E, Franceschi S, LaVecchia C (2007) Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol 196(1):83 e81–e87. doi:10.​1016/​j.​ajog.​2006.​06.​088 CrossRef
133.
Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, Conti E, Montella M, La Vecchia C (2001) Reproductive and hormonal factors and ovarian cancer. Ann Oncol 12(3):337–341PubMedCrossRef
134.
Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C (1993) Risk factors for epithelial ovarian cancer in women under age 45. Eur J Cancer 29A(9):1297–1301PubMedCrossRef
135.
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR (2002) Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156(4):363–373PubMedCrossRef
136.
Chiaffarino F, Pelucchi C, Negri E, Parazzini F, Franceschi S, Talamini R, Montella M, Ramazzotti V, La Vecchia C (2005) Breastfeeding and the risk of epithelial ovarian cancer in an Italian population. Gynecol Oncol 98(2):304–308. doi:10.​1016/​j.​ygyno.​2005.​05.​006 PubMedCrossRef
137.
Booth M, Beral V, Smith P (1989) Risk factors for ovarian cancer: a case-control study. Br J Cancer 60(4):592–598PubMedCrossRef
138.
139.
140.
141.
142.
Siskind V, Green A, Bain C, Purdie D (1997) Breastfeeding, menopause, and epithelial ovarian cancer. Epidemiology 8(2):188–191PubMedCrossRef
143.
Rosenblatt KA, Thomas DB (1993) Lactation and the risk of epithelial ovarian cancer. The WHO collaborative study of neoplasia and steroid contraceptives. Int J Epidemiol 22(2):192–197PubMedCrossRef
144.
Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM (1983) Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 117(2):128–139PubMed
145.
Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative ovarian cancer group. Am J Epidemiol 136(10):1184–1203PubMed
146.
147.
148.
149.
150.
Purdie DM, Siskind V, Bain CJ, Webb PM, Green AC (2001) Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 153(9):860–864PubMedCrossRef
151.
McNeilly AS (2001) Lactational control of reproduction. Reprod Fertil Dev 13(7–8):583–590PubMedCrossRef
152.
Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson PO (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344(8932):1250–1254. pii: S0140-6736(94)90749-8PubMedCrossRef
153.
Risch HA, Marrett LD, Howe GR (1994) Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140(7):585–597PubMed
154.
Liu Q, Lambe M, Baik I, Cnattingius S, Riman T, Ekbom A, Adami HO, Hsieh CC (2006) A prospective study of the transient decrease in ovarian cancer risk following childbirth. Cancer Epidemiol Biomarkers Prev 15(12):2508–2513. doi:10.​1158/​1055-9965.​EPI-06-0242 PubMedCrossRef
155.
156.
Whiteman DC, Murphy MF, Cook LS, Cramer DW, Hartge P, Marchbanks PA, Nasca PC, Ness RB, Purdie DM, Risch HA (2000) Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 92(14):1172–1177PubMedCrossRef
157.
Albrektsen G, Heuch I, Kvale G (1996) Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes Control 7(4):421–427PubMedCrossRef
158.
Chen MT, Cook LS, Daling JR, Weiss NS (1996) Incomplete pregnancies and risk of ovarian cancer (Washington, United States). Cancer Causes Control 7(4):415–420PubMedCrossRef
159.
Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, Quinn M, Wright G, Russell P, Susil B (1995) Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of women’s health study group. Int J Cancer 62(6):678–684PubMedCrossRef
160.
Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE (1995) A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76(2):284–290PubMedCrossRef
161.
Bernal A, Mendez-Moran L, Fajardo-Gutierrez A, Gonzalez-Lira G, Escudero P, Ortiz H (1995) Univariate and multivariate analysis of risk factors for ovarian cancer: case-control study. Mexico City. Arch Med Res 26(3):245–249
162.
Lund E (1992) Mortality from ovarian cancer among women with many children. Int J Epidemiol 21(5):872–876PubMedCrossRef
163.
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 83(3):575–585. doi:10.​1006/​gyno.​2001.​6451 PubMedCrossRef
164.
Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR (1988) Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 48(20):5849–5852PubMed
165.
Harris R, Whittemore AS, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative ovarian cancer group. Am J Epidemiol 136(10):1204–1211PubMed
166.
Parazzini F, Restelli C, La Vecchia C, Negri E, Chiari S, Maggi R, Mangioni C (1991) Risk factors for epithelial ovarian tumours of borderline malignancy. Int J Epidemiol 20(4):871–877PubMedCrossRef
167.
168.
Risch HA, Marrett LD, Jain M, Howe GR (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144(4):363–372PubMedCrossRef
169.
Kvale G, Heuch I, Nilssen S, Beral V (1988) Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 42(2):246–251PubMedCrossRef
170.
171.
Jordan SJ, Green AC, Nagle CM, Olsen CM, Whiteman DC, Webb PM (2009) Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics. Am J Epidemiol 170(5):607–614. doi:10.​1093/​aje/​kwp185 PubMedCrossRef
172.
Brinton LA, Melton LJ 3rd, Malkasian GD Jr, Bond A, Hoover R (1989) Cancer risk after evaluation for infertility. Am J Epidemiol 129(4):712–722PubMed
173.
Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B (1998) Cancer incidence in a cohort of infertile women. Am J Epidemiol 147(11):1038–1042PubMedCrossRef
174.
Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A (1999) Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 71(5):853–859. pii: S0015-0282(99)00085-0PubMedCrossRef
175.
176.
Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH (2002) Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155(3):217–224PubMedCrossRef
177.
Rodriguez C, Tatham LM, Calle EE, Thun MJ, Jacobs EJ, Heath CW Jr (1998) Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control 9(6):645–651PubMedCrossRef
178.
Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG (2004) A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 160(11):1070–1078. doi:10.​1093/​aje/​kwh315 PubMedCrossRef
179.
Jensen A, Sharif H, Olsen JH, Kjaer SK (2008) Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol 168(1):49–57. doi:10.​1093/​aje/​kwn094 PubMedCrossRef
180.
Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE (2007) Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 166(8):894–901. doi:10.​1093/​aje/​kwm157 PubMedCrossRef
181.
182.
183.
Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4):385–394. doi:10.​1016/​S1470-2045(11)70404-1 PubMedCrossRef
184.
Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C (1996) Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88(4 Pt 1):554–559PubMedCrossRef
185.
Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S (2009) Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 19(3):398–405PubMedCrossRef
186.
Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F (1976) Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 57(5):1320–1329. doi:10.​1172/​JCI108400 PubMedCrossRef
187.
Baird DT, Corker CS, Davidson DW, Hunter WM, Michie EA, Van Look PF (1977) Pituitary-ovarian relationships in polycystic ovary syndrome. J Clin Endocrinol Metab 45(4):798–801PubMedCrossRef
188.
Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 335(7621):651. doi:10.​1136/​bmj.​39289.​649410.​55 PubMedCrossRef
189.
190.
191.
192.
193.
Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL, Harlap S, Shapiro S (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139(7):654–661PubMed
194.
Walker GR, Schlesselman JJ, Ness RB (2002) Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 186(1):8–14. pii: S0002937802860628PubMedCrossRef
195.
Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE (2001) Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 12(3):307–312PubMedCrossRef
196.
Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G (1999) Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study. BMJ 318(7176):96–100PubMedCrossRef
197.
Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL (1990) Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 43(6):559–568. pii: 0895-4356(90)90160-QPubMedCrossRef
198.
Rosenberg L, Shapiro S, Slone D, Kaufman DW, Helmrich SP, Miettinen OS, Stolley PD, Rosenshein NB, Schottenfeld D, Engle RL Jr (1982) Epithelial ovarian cancer and combination oral contraceptives. JAMA 247(23):3210–3212PubMedCrossRef
199.
Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609):303–314. doi:10.​1016/​S0140-6736(08)60167-1 PubMedCrossRef
200.
201.
Wittenberg J, Cook LS, Rossing MA, Weiss NS (1999) Reproductive risk factors for mucinous and non-mucinous epithelial ovarian cancer. Epidemiology 10(6):761–763PubMedCrossRef
202.
Siskind V, Green A, Bain C, Purdie D (2000) Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 11(2):106–110PubMedCrossRef
203.
204.
Bosetti C, Negri E, Franceschi S, Trichopoulos D, Beral V, La Vecchia C (2001) Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 285 (24):3089; author reply 3090. pii: jlt0627-2
205.
Garg PP, Kerlikowske K, Subak L, Grady D (1998) Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92(3):472–479. pii: S0029-7844(98)00139-2PubMedCrossRef
206.
Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288(3):334–341. pii: joc20074PubMedCrossRef
207.
208.
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR (2002) Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94(7):497–504PubMedCrossRef
209.
Ortmann O, Doren M, Windler E (2011) Hormone therapy in perimenopause and postmenopause (HT). Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 284(2):343–355. doi:10.​1007/​s00404-011-1878-x PubMedCrossRef
210.
Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Danforth KN, Park Y, Brinton LA (2012) Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 107(7):1181–1187. doi:10.​1038/​bjc.​2012.​397 PubMedCrossRef
211.
212.
Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 290(13):1739–1748. doi:10.​1001/​jama.​290.​13.​1739 PubMedCrossRef
213.
Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285(11):1460–1465. pii: joc01947PubMedCrossRef
214.
215.
216.
217.
Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV (2010) Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen. Int J Cancer 127(12):2928–2935. doi:10.​1002/​ijc.​25515 PubMedCrossRef
218.
Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, Hartge P (2006) Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98(19):1397–1405. doi:10.​1093/​jnci/​djj375 PubMedCrossRef
219.
220.
221.
Tsilidis KK, Allen NE, Key TJ, Dossus L, Kaaks R, Bakken K, Lund E, Fournier A, Dahm CC, Overvad K, Hansen L, Tjonneland A, Rinaldi S, Romieu I, Boutron-Ruault MC, Clavel-Chapelon F, Lukanova A, Boeing H, Schutze M, Benetou V, Palli D, Berrino F, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodriguez L, Duell EJ, Sanchez MJ, Huerta JM, Ardanaz E, Amiano P, Khaw KT, Wareham N, Riboli E (2011) Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22(8):1075–1084. doi:10.​1007/​s10552-011-9782-z PubMedCrossRef
222.
223.
224.
225.
Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, Hartge P, Hollenbeck A, Park Y, Wentzensen N (2012) Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer 131(4):938–948. doi:10.​1002/​ijc.​26469 PubMedCrossRef
226.
Matei MC, Caruntu ID, Negura L, Petrariu FD, Ifrim S, Acatrinei L, Sulugiuc A, Azoicai D (2010) The assessment of relations between main histologic type of ovarian cancer and some risk and prognostic factors. Rev Med Chir Soc Med Nat Iasi 114(4):1135–1141PubMed
227.
228.
229.
Martinez F, Manubens M, Carreras O, Tur R, Barri PN (1993) Ovarian function during hormonal replacement therapy in perimenopausal women. Adv Contracept 9(1):71–74PubMedCrossRef
230.
Gebbie AE, Glasier A, Sweeting V (1995) Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contraception 52(4):221–222. pii: 001078249500184CPubMedCrossRef
231.
Waaseth M, Bakken K, Dumeaux V, Olsen KS, Rylander C, Figenschau Y, Lund E (2008) Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort—a cross-sectional analysis. BMC Womens Health 8:1. doi:10.​1186/​1472-6874-8-1 PubMedCrossRef
232.
233.
Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, Bergh T, Hagenfeldt K, Janson PO, Nilsson S, Persson I (2009) Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril 91(4):1152–1158. doi:10.​1016/​j.​fertnstert.​2008.​01.​073 PubMedCrossRef
234.
Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG (1996) Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 65(1):13–18PubMed
235.
Parazzini F, Negri E, La Vecchia C, Moroni S, Polatti A, Chiaffarino F, Surace M, Ricci E (1998) Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 68(3):226–228. doi:10.​1006/​gyno.​1997.​4928 PubMedCrossRef
236.
Goldberg GL, Runowicz CD (1992) Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation–is there a link? Am J Obstet Gynecol 166(3):853–854. pii: 0002-9378(92)91348-EPubMedCrossRef
237.
van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, Laven JS, Jansen CA, Helmerhorst FM, Cohlen BJ, Willemsen WN, Smeenk JM, Simons AH, van der Veen F, Evers JL, van Dop PA, Macklon NS, Burger CW (2011) Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 26(12):3456–3465. doi:10.​1093/​humrep/​der322 PubMedCrossRef
238.
Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN (1998) Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 70(6):1049–1055. pii: S0015028298003379PubMedCrossRef
239.
Parazzini F, Negri E, La Vecchia C, Moroni S, Franceschi S, Crosignani PG (1997) Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 12(10):2159–2161PubMedCrossRef
240.
Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN (1997) Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 67(6):1005–1012. pii: S0015028297814318PubMedCrossRef
241.
Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL (2002) Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 17(8):2209–2213PubMedCrossRef
242.
Kurta ML, Moysich KB, Weissfeld JL, Youk AO, Bunker CH, Edwards RP, Modugno F, Ness RB, Diergaarde B (2012) Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study. Cancer Epidemiol Biomarkers Prev 21(8):1282–1292. doi:10.​1158/​1055-9965.​EPI-12-0426 PubMedCrossRef
243.
244.
245.
Jensen A, Jensen A, Sharif H, Sharif H, Frederiksen K, Frederiksen K (2009) Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ British Medical
246.
Metadaten
Titel
Ovarian epithelial tumors and reproductive factors: a systematic review
verfasst von
Susanne Schüler
Marvin Ponnath
Jörg Engel
Olaf Ortmann
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 6/2013
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-013-2784-1

Weitere Artikel der Ausgabe 6/2013

Archives of Gynecology and Obstetrics 6/2013 Zur Ausgabe

General Gynecology

Female genital mutilation and infections: a systematic review of the clinical evidence

Letter to the Editor

Bilateral transient osteoporosis of the knee during pregnancy

Maternal-Fetal Medicine

The outcomes of trial of labour after cesarean section following induction of labour compared to spontaneous labour

Reproductive Medicine

Relationship of leptin administration with production of reactive oxygen species, sperm DNA fragmentation, sperm parameters and hormone profile in the adult rat

Reproductive Medicine

Serum calcitonin gene-related peptide levels in women with polycystic ovary syndrome

Gynecologic Oncology

Chest wall resection and reconstruction for locally advanced primary breast cancer

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise